Drug Profile
Research programme: kallikrein inhibitors - IBEX
Latest Information Update: 14 Apr 2011
Price :
$50
*
At a glance
- Originator IBEX Technologies
- Class
- Mechanism of Action Kallikrein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Ovarian cancer; Prostate cancer
Most Recent Events
- 12 Jan 2005 Preclinical trials in Ovarian cancer in Canada (unspecified route)
- 12 Jan 2005 Preclinical trials in Prostate cancer in Canada (unspecified route)